Literature DB >> 15451492

Could disease-modifying HIV vaccines cause population-level perversity?

Robert J Smith1, Sally M Blower.   

Abstract

Most current candidate HIV vaccines seem to produce little protection against infection, but reduce viral load and slow the decline in CD4 lymphocyte numbers. Such disease-modifying vaccines could potentially provide important population-level benefits by reducing transmission, but could possibly also increase transmission. We address the following question: could disease-modifying HIV vaccines cause population-level perversity (ie, increase epidemic severity)? By analysing a mathematical model and defining a new quantity-the fitness ratio-we show that disease-modifying vaccines that provide only a low degree of protection against infection and/or generate high fitness ratios will have a high probability of making the epidemic worse. However, we show that if disease-modifying vaccines cause a 1.5 log(10) reduction in viral load (or greater) then perversity cannot occur (assuming risk behaviour does not increase). Finally, we determine threshold surfaces for risk behaviour change that determine the boundary between beneficial and perverse outcomes; the threshold surfaces are determined by the fitness ratio, the proportion of the population that are "successfully vaccinated", and the degree of change of risk behaviour in unvaccinated infected individuals. We discuss the implications of our results for designing optimal vaccination control strategies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15451492     DOI: 10.1016/S1473-3099(04)01148-X

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  17 in total

1.  High-potency human immunodeficiency virus vaccination leads to delayed and reduced CD8+ T-cell expansion but improved virus control.

Authors:  Miles P Davenport; Lei Zhang; Ansuman Bagchi; Arthur Fridman; Tong-Ming Fu; William Schleif; John W Shiver; Ruy M Ribeiro; Alan S Perelson
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

2.  A susceptible-infected epidemic model with voluntary vaccinations.

Authors:  Frederick H Chen
Journal:  J Math Biol       Date:  2006-06-07       Impact factor: 2.259

3.  Mathematical models for HIV transmission dynamics: tools for social and behavioral science research.

Authors:  Susan Cassels; Samuel J Clark; Martina Morris
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731

4.  HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis.

Authors:  Virginie Supervie; J Gerardo García-Lerma; Walid Heneine; Sally Blower
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

5.  ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial.

Authors:  Irini Sereti; Roy M Gulick; Sonya Krishnan; Stephen A Migueles; Adrian Palfreeman; Veronique Touzeau-Römer; Waldo H Belloso; Sean Emery; Matthew G Law
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-01       Impact factor: 3.731

6.  Potential population health outcomes and expenditures of HIV vaccination strategies in the United States.

Authors:  Elisa F Long; Margaret L Brandeau; Douglas K Owens
Journal:  Vaccine       Date:  2009-07-08       Impact factor: 3.641

7.  Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example.

Authors:  Kyeen M Andersson; Douglas K Owens; Eftyhia Vardas; Glenda E Gray; James A McIntyre; A David Paltiel
Journal:  J Acquir Immune Defic Syndr       Date:  2007-09-01       Impact factor: 3.731

8.  HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.

Authors:  Joshua T Herbeck; Kathryn Peebles; Paul T Edlefsen; Morgane Rolland; James T Murphy; Geoffrey S Gottlieb; Neil Abernethy; James I Mullins; John E Mittler; Steven M Goodreau
Journal:  Vaccine       Date:  2017-12-11       Impact factor: 3.641

9.  Modeling HIV vaccines in Brazil: assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV.

Authors:  Maria Goretti P Fonseca; Steven Forsythe; Alexandre Menezes; Shilpa Vuthoori; Cristina Possas; Valdiléa Gonçalves Veloso; Valdiléa Veloso; Francisca de Fátima Lucena; John Stover
Journal:  PLoS One       Date:  2010-07-23       Impact factor: 3.240

10.  Network effects of risk behavior change following prophylactic interventions.

Authors:  Rajmohan Rajaraman; Zhifeng Sun; Ravi Sundaram; Anil Kumar S Vullikanti
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.